IL1RL2 and pustular psoriasis: Spesolimab, an IL-36 receptor (IL-36R) inhibitor, blocks IL-36R activation and has demonstrated significant efficacy in treating pustular psoriasis,[4] establishing it as a potent therapeutic option.